Pressurized IntraThoracic Aerosol Chemotherapy (PITAC) directed therapy of patients with malignant pleural effusion and pleural metastasis

• DOI: 10.1515/pp-2024-0008
• Publication Date: 2024-11-20T20:23:21Z
• Authors: Pernille Schjødt ...; Martin Graversen; Sönke Detlefsen; Alan Patrick Ains...; Michael Bau Morte...
• Keywords: thoracic regression grading score (trgs); pressurized intrathoracic aerosol chemotherapy (PITAC); R; palliative treatment; Specialties of internal medicine; pressurized intrathoracic aerosol chemotherapy (pitac); pleural metastasis; Article; 03 medical and health sciences; 0302 clinical medicine; RC581-951; thoracic regression grading score (TRGS); Medicine; malignant pleural effusion

Pressurized IntraThoracic Aerosol Chemotherapy (PITAC) has been suggested as a new therapy for patients with malignant pleural effusion (MPE) and/or metastasis (PLM). The have poor prognosis median survival of 3 to 12 months. We present feasibility, patient safety, and cytological/histological response assessment in PITAC-treated MPE PLM.